These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30942881)

  • 21. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
    Castillo-Mancilla JR; Searls K; Caraway P; Zheng JH; Gardner EM; Predhomme J; Bushman LR; Anderson PL; Meditz AL
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):428-32. PubMed ID: 25328112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    van Heerden JK; Meintjes G; Barr D; Zhao Y; Griesel R; Keene CM; Wiesner L; Galileya LT; Denti P; Maartens G
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):260-267. PubMed ID: 38408216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.
    Mann SC; Morrow M; Coyle RP; Coleman SS; Saderup A; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):483-488. PubMed ID: 33136749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
    AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence.
    Abuogi LL; Castillo-Mancilla J; Hampanda K; Owuor K; Odwar T; Onono M; Helova A; Turan JM; Anderson PL
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):310-317. PubMed ID: 34889866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
    Castillo-Mancilla JR; Coyle RP; Coleman SS; Morrow M; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2020 Mar; 36(3):173-175. PubMed ID: 31204866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
    Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future Viremia.
    Grinsteiner E; Morrow M; Mawhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
    AIDS Res Hum Retroviruses; 2023 Jan; 39(1):33-37. PubMed ID: 36301917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
    Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
    Tsuchiya K; Hayashi Y; Ryu S; Tran HT; Takano M; Tanaka K; Mizushima D; Oka S; Gatanaga H; Hamada A
    J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF).
    Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR
    Clin Infect Dis; 2024 Nov; 79(5):1233-1241. PubMed ID: 38636950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
    Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
    Peterson S; Ibrahim M; Anderson PL; Moore CM; MaWhinney S
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):655-669. PubMed ID: 34013454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility.
    Mustanski B; Ryan DT; Spinelli MA; Gandhi M; Newcomb ME
    AIDS; 2023 Dec; 37(15):2381-2387. PubMed ID: 37696260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; MaWhinney S
    Open Forum Infect Dis; 2021 Sep; 8(9):ofab463. PubMed ID: 34584902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.